Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access study of sotorasib for previously treated KRAS G12C-mutated advanced non-small cell lung cancer
2020-005279-11Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jun 2021; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005279-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005279-11.